Madison Muller, a Bloomberg News Health Care Reporter, dives into groundbreaking research revealing that Eli Lilly's ZEP Bound can reduce diabetes risk by 94% in obese patients over three years. She discusses the significant long-term health benefits of weight-loss drugs and their role in battling chronic diseases like type 2 diabetes. The conversation also covers the shift from injections to pills in drug delivery and the fierce competition among pharmaceutical firms driving these innovations.
Read more
AI Summary
AI Chapters
Episode notes
auto_awesome
Podcast summary created with Snipd AI
Quick takeaways
Eli Lilly's weight loss drug significantly reduces diabetes risk by 94% in obese patients, revealing the critical health benefits of tackling obesity.
GLP-1 medications not only aid in substantial weight loss but also present potential advantages for overall health, including heart health improvements.
Deep dives
Gen AI as the New Operating System
Gen AI is poised to become the fundamental framework for the internet, integrating into all products, services, and applications. Businesses are encouraged to start their AI journey to harness the performance enhancements it offers. For instance, Netflix improved its streaming performance by over 350% through the use of Intel's AI accelerators, which outperform rival technologies by 30%. Implementing AI solutions on trusted architectures can significantly boost operational efficiency and effectiveness.
Long-Term Benefits of Weight Loss Drugs
A three-year study reveals that patients using Eli Lilly's weight loss drug saw a 94% reduction in diabetes risk, highlighting the long-term health advantages of obesity treatment. The participants lost an average of 23% of their weight over the study period, underlining the efficacy of GLP-1 medications. Though these drugs primarily target weight loss, they also offer significant benefits to overall health, such as improved heart health and diabetes prevention. Researchers are exploring broader applications for these drugs, including conditions like osteoarthritis and inflammatory diseases, indicating their potential in addressing various health issues.
Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF. Bloomberg News Health Care Reporter Madison Muller discusses that patients taking Eli Lilly’s blockbuster weight-loss shot were 94% less likely to develop diabetes in a three-year study that illuminates the long-term health benefits of treating obesity. Hosts: Tim Stenovec and Katie Greifeld. Producer: Paul Brennan.